Pleural Biphasic Mesothelioma
NCI Definition: Malignant mesothelioma that arises from the pleura. It is characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor. 
Pleural biphasic mesotheliomas most frequently harbor alterations in BAP1, CDKN2A, NF2, CDKN2B, and TP53 .
CDKN2A Loss, NF2 Mutation, CDKN2B Loss, BAP1 Mutation, and NF2 Frameshift are the most common alterations in pleural biphasic mesothelioma .
There are 4 clinical trials for pleural biphasic mesothelioma, of which 4 are open and 0 are completed or closed. Of the trials that contain pleural biphasic mesothelioma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).
Mk-4830, celecoxib, and cisplatin are the most common interventions in pleural biphasic mesothelioma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.